Life science company Addlife has reported a decrease in revenue for the fourth quarter compared to the same period last year. Adjusted operating profit (EBITA) also declined. However, the board is proposing a higher dividend.
Revenue fell by 3.0 percent to SEK 2,733 million (2,818). Organic sales growth was 1 percent (9).
Gross profit amounted to SEK 1,041 million (1,044), with a gross margin of 38.1 percent (37.0).
EBITA reached SEK 497 million (346), with an EBITA margin of 18.2 percent (12.3).
Adjusted EBITA was SEK 339 million (346).
Operating profit totaled SEK 393 million (229), with an operating margin of 14.4 percent (8.1).
Profit before tax was SEK 343 million (150).
Net profit after tax came to SEK 260 million (94), or SEK 2.12 per share (0.76).
The ordinary dividend proposed is SEK 1.50 per share (0.75).
Cash flow from operating activities amounted to SEK 888 million (666).
AddLife AB is a Sweden-based company, which is primarily involved in the healthcare industry. The Company markets and sells instruments, equipment, consumables and related services mainly to the healthcare sector. The Company operates through two segments: The LabTech segment is engaged in the sales of laboratory equipment, analytical instruments and reagents, that are used for diagnostics or biomedical research; The MedTech segment offers various medical device equipment, consumables, instruments and devices, primarily to hospitals. The Company operates through number of subsidiaries, such as BergmanLabora AB, BioNordica group, Holm & Halby A/S, Immuno Diagnostic Oy, LabRobot Products AB, Triolab-group, Active Care Sverup AB, Fenno Medical Oy, Mediplast AB, among others.
